When biomarker concentrations of all patient samples were plotted in chronological order of assaying, it appeared that there was a sufficient window of variation within a positively skewed distribution. In general there was no evident variation over time and between assays, except for two remarkable observations: For the sCOMP assay there was a clear difference in measured biomarker concentrations between the first 6 kits and last 8 kits.
Purpose: 1) To determine the association of 31 biomarkers with pre-radiographic and radiographic symptomatic knee OA compared to symptomatic controls; 2) to determine if latent biomarker factors determined by principal components based factor analysis (PC-FA) are better able to distinguish OA stage compared to individual biomarkers. PC-FA, in addition to revealing potential underlying factors, may be useful to overcome problems of multiple comparisons and may help stabilize variance. Methods: 255 subjects, 40-79 years, with knee pain were assembled, stratified by age decade and gender, in a cross-sectional population-based study and evaluated with MRI, xray and biomarkers. MR cartilage (MRC) defects (score 0-4) and x-rays (Kellgren-Lawrence [KL] grade 0-4) were read blinded. Subjects were classified as No OA (NOA) (KL<2, MRC=0), Pre-Radiographic OA (PROA) (KL<2, MRC≥1) or Radiographic OA (ROA) (KL≥2, MRC≥1). Serum levels of matrix metalloproteinases (MMPs) 1, 3 and 9, tissue inhibitor of MMP, interleukins 1a, 1b, 4, 6, 7, 8, 10, 17A, tumor necrosis factor, c-telopeptide of type I collagen (CTX-I), adiponectin, resistin, eotaxin, C-reactive protein, hyaluronic acid (HA) and other cytokines were evaluated. PC-FA was performed using individual biomarkers and ratios of markers previously measured, including urine c-telopeptide of type II collagen (uCTX-II), urine and serum type II and types I and II collagen cleavage neoepitopes (C2C and C1,2C respectively), c-propeptide of type II procollagen (CPII), 846 epitope, and urine n-telopeptide of type I collagen (uNTX-I). Multicategory logistic regression (adjusted for age, sex and BMI) was used to evaluate the association of OA category with each log transformed biomarker, biomarker ratio, and biomarker factor, incorporating stratum sampling weights. Standardized (i.e. per standard deviation change) odds ratios (ORs) were reported to enable comparison of the ORs across biomarker variables.
Results: Significant associations with PROA vs NOA were seen for MMP-9 (OR 1.60, 95% CI 1.00-2.57), uC2C (OR 2.34, 95% CI 1.34-4.09), uC1,2C (OR 1.99, 95% CI 1.24-3.19), and uC2C/sCPII ratio (OR 2.41, 95% CI 1.33-4.37). Risk of ROA vs NOA was significantly increased for uCTX-II (OR 2.97, 95% CI 1.45-6.08), uC2C (OR 2.28, 95% CI 1.23-4.22), uC1,2C (OR 2.08, 95% CI 1.21-3.56), uCTX-II/sCPII (OR 2.62, 95% CI 1.35-5.06) and uC2C/sCPII (OR 2.55, 95% CI 1. 32-4.95) . PC-FA identified 4 clinically interpretable factors, of which one factor (determined largely by uCTX-II, uC2C, uNTX-I, CTX-I, uC1,2C, and HA) was significantly associated with PROA (OR 2.08, 95% CI 1. 04-4.14) and with ROA (OR 2.52, . PC-FA with inclusion of biomarker ratios resulted in similar findings. The strength of association with PROA and ROA was similar for individual biomarkers, biomarker ratios and biomarker factors.
Conclusions:
In this population-based study, several biomarkers were significantly associated with PROA (MMP-9, uC2C and uC1,2C), and with uC2C, uC1, 2C) . Discrimination of OA groups within this cohort was not improved using biomarker factors (determined by factor analysis) over individual biomarkers or biomarker ratios.
